MetaCap

SAB Biotherapeutics (SABS) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SAB Biotherapeutics is the larger company by market cap ($253.1 million vs $228.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SABS-18.31%SCTX-36.37%
+103%+30%-43%
Jul 27, 20261 yearNov 20, 2026
SABS-21.29%SCTX-38.04%
+81%+19%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SABS versus SCTX key metrics
MetricSABSSCTX
Share price$2.81$12.07
Market cap$253.15M$228.58M
1-day change-3.44%-8.70%
YTD return-24.87%—
1-year return-28.86%—
5-year return-97.32%—
EPS (TTM)$-1.35$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$13.27M—
52-week high$5.15$39.60
52-week low$2.44$12.00
Distance from 52-week high-45.44%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+314.23%+372.25%
Average volume633.60K403.27K
Shares outstanding90.09M18.94M
Employees8677
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About SAB Biotherapeutics

SABS stock →

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

SABS vs SCTX FAQ

Which is bigger, SAB Biotherapeutics or Scribe Therapeutics?

SAB Biotherapeutics (SABS) is larger, with a market capitalization of $253.15M compared with $228.58M for Scribe Therapeutics (SCTX).

Are SAB Biotherapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons